Kaléo Announces License Agreement with Amgen for Auto-Injector Technology

Glen Allen, VA, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Kaléo today announced that it has entered into a confidential license agreement with Amgen Inc. Under the terms of the agreement, Amgen obtained a license to certain of Kaléo's patented technology on auto-injectors. This agreement reflects Kaléo's innovative contribution to drug-device technologies and longstanding leadership in advancing patient-centric auto-injector solutions. Financial and other terms of the agreement were not disclosed.

About Kaléo

Kaléo is a pharmaceutical company and global leader in drug-delivery device technology and auto-injector innovation, providing millions of patients with security and peace of mind. Our patented Aerio™ platform, with unmatched capabilities and human factors engineering, powers our portfolio of auto-injector products, as well as products under development for third parties. Visit www.kaleo.com.

###

CC-US-0234

Carrie Siragusa 
Kaléo
media.inquiries@kaleo.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.